Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Science (New York, N.Y.) - 9 Oct 2015

Van Allen Eliezer M, Miao Diana, Schilling Bastian, Shukla Sachet A, Blank Christian, Zimmer Lisa, Sucker Antje, Hillen Uwe, Foppen Marnix H Geukes, Goldinger Simone M, Utikal Jochen, Hassel Jessica C, Weide Benjamin, Kaehler Katharina C, Loquai Carmen, Mohr Peter, Gutzmer Ralf, Dummer Reinhard, Gabriel Stacey, Wu Catherine J, Schadendorf Dirk, Garraway Levi A

Abstract excerpt

Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic melanoma by inhibiting immune checkpoint activity, but clinical predictors of response to these therapies remain incomp...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Checkpoints

Share to CTLA-4 Antigen

Share to HLA Antigens

Share to Ipilimumab

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 26359337
DOI: 10.1126/science.aad0095
PMCID: PMC5054517

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26359337-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.PMID 26359337Read ↗

Genetic basis for clinical response to CTLA-4 blockade in melanoma.Semantic proximity Read ↗

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.Semantic proximity Read ↗

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade.Semantic proximity Read ↗

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeSemantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Semantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in MelanomaSemantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance MechanismsSemantic proximity Read ↗

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read ↗

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.